← All trials
NCT04488601
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2020
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Jul 28, 2020
- Last posted
- Jul 28, 2020
- Enrollment
- 1000
- Arms / groups
- 7 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AgelessRxLead sponsor
- AgelessRxStudy director
- University of California, Los AngelesCollaborator
- AgelessRxOfficial
- University of California, Los AngelesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.